P4‐002: A Phase 3, 26‐Week, Double‐Blind, Randomized, Placebo‐Controlled Study of AC‐1204 in Mild‐to‐Moderate Alzheimer's Disease: Study Design and Progress | Zendy

Farlow Martin R. | Zendy; Gold Michael | Zendy; Henderson Samuel | Zendy; Greer Sabrina | Zendy; Vogel Janet | Zendy; Shenkin Aaron | Zendy

Premium

P4‐002: A Phase 3, 26‐Week, Double‐Blind, Randomized, Placebo‐Controlled Study of AC‐1204 in Mild‐to‐Moderate Alzheimer's Disease: Study Design and Progress

Author(s) -

Farlow Martin R.,

Gold Michael,

Henderson Samuel,

Greer Sabrina,

Vogel Janet,

Shenkin Aaron

Publication year - 2016

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2016.06.2091

Subject(s) - placebo , ketosis , medicine , randomized controlled trial , dementia , clinical endpoint , disease , pediatrics , endocrinology , diabetes mellitus , pathology , alternative medicine

P4-001 A LARGE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING RVT-101, A NEUROTRANSMITTER-TARGETED THERAPY, IN SUBJECTS WITH MILD-TOMODERATE ALZHEIMER’S DISEASE ON DONEPEZILTREATMENT: PHASE 3 MINDSET STUDY DESIGN Ilise Lombardo, Shari Coslett, David W. Liu, Kunal S. Kishnani, Benjamin Zimmer, Lawrence Friedhoff, Axovant Sciences, Inc., New York, NY, USA; 2 Roivant Sciences, Inc., New York, NY, USA. Contact e-mail: ilise.lombardo@axovant.com

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research